PMID- 10802150
OWN - NLM
STAT- MEDLINE
DCOM- 20000623
LR  - 20190910
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 48
IP  - 2
DP  - 2000 May
TI  - IDL can stimulate atherogenic gene expression in cultured human vascular 
      endothelial cells.
PG  - 127-38
AB  - Previously, we have reported that the lipoprotein fraction containing 
      intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) isolated 
      from diabetics stimulates an atherogenic cytokine in cultured endothelial cells. 
      To study which lipoprotein fraction isolated from diabetics can modulate the gene 
      expression in endothelial cells, we isolated IDL and LDL fractions from 14 type 2 
      diabetics and seven age- and BMI- adjusted non-diabetics. We measured the effects 
      of the lipoproteins on mRNA expression of atherogenic molecules in cultured 
      endothelial cells. We found that the IDL fraction stimulated monocyte 
      chemoattractant protein-1 (MCP-1) mRNA expression in endothelial cells as time- 
      and dose-dependent fashions, while the LDL fraction was not effective. IDL 
      isolated from diabetics also increased not only platelet-derived growth factor 
      B-chain, but also intercellular adhesion molecule-1 mRNA contents. Furthermore, 
      the HbA(1c) levels in diabetics were significantly correlated with their 
      abilities of IDL to increase MCP-1 mRNA content in the cells and the increment 
      coincided with the increase in MCP-1 protein release into culture media. These 
      results indicate that qualitative as well as quantitative changes in IDL fraction 
      in diabetes are atherogenic through stimulating gene expression of atherogenic 
      molecules in endothelial cells.
FAU - Maeno, Y
AU  - Maeno Y
AD  - Third Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, 
      Japan.
FAU - Kashiwagi, A
AU  - Kashiwagi A
FAU - Nishio, Y
AU  - Nishio Y
FAU - Takahara, N
AU  - Takahara N
FAU - Kikkawa, R
AU  - Kikkawa R
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Chemokine CCL2)
RN  - 0 (Lipoproteins)
RN  - 0 (Lipoproteins, IDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Triglycerides)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Arteriosclerosis
MH  - Cells, Cultured
MH  - Chemokine CCL2/*genetics
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Endothelium, Vascular/*metabolism
MH  - Female
MH  - Gene Expression Regulation/*physiology
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/*genetics
MH  - Lipoproteins/*blood/isolation & purification/*pharmacology
MH  - Lipoproteins, IDL
MH  - Lipoproteins, LDL/blood/isolation & purification/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Platelet-Derived Growth Factor/*genetics
MH  - RNA, Messenger
MH  - Reference Values
MH  - *Transcription, Genetic
MH  - Triglycerides/blood
MH  - Umbilical Veins
EDAT- 2000/05/10 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/05/10 09:00
PHST- 2000/05/10 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/05/10 09:00 [entrez]
AID - S0168-8227(99)00147-3 [pii]
AID - 10.1016/s0168-8227(99)00147-3 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2000 May;48(2):127-38. doi: 
      10.1016/s0168-8227(99)00147-3.